SCHEMBL5089823

SCHEMBL5089823

CN(C)CCc1c2n(c3c(Cl)cc(Cl)c(Cl)c13)C(=O)c1ccccc1-2

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HEXA P06865 1/20 0.36
▸ HEXB P07686 1/20 0.36
▸ HTR6 P50406 7/20 0.36
▸ TAAR1 Q96RJ0 1/20 0.35
▸ HTR1A P08908 4/20 0.34
▸ HTR2A P28223 4/20 0.34
▸ HTR7 P34969 3/20 0.34
▸ NR1I2 O75469 1/20 0.34
▸ POLB P06746 1/20 0.34
▸ AHR P35869 1/20 0.34
▸ RAD52 P43351 1/20 0.34
▸ RCE1 Q9Y256 1/20 0.34
▸ HTR1D P28221 1/20 0.34
▸ HTR1B P28222 1/20 0.34
▸ HTR1E P28566 1/20 0.34
▸ HTR2B P41595 1/20 0.34
▸ HTR5A P47898 1/20 0.34
▸ DRD2 P14416 4/20 0.33
▸ SLC6A4 P31645 3/20 0.33
▸ HRH1 P35367 3/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5101426 0.82 HTR6 (0.40) HTR6TAAR1HTR1AHTR2AHTR7
SCHEMBL5094651 0.82 HEXA (0.35) HEXAHEXBHTR6TAAR1HTR1A
SCHEMBL5101367 0.81 HTR6 (0.40) HEXAHEXBHTR6TAAR1HTR1A
SCHEMBL5089911 0.80 HTR6 (0.44) HEXAHEXBHTR6TAAR1HTR1A
SCHEMBL5767358 0.78 MAT2A (0.41) HEXAHEXBHTR6TAAR1HTR1A
SCHEMBL5089826 0.76 KMT2A (0.31) KDM4EALDH1A1LMNA
SCHEMBL5095541 0.76 HTR6 (0.40) HEXAHEXBHTR6HTR1AHTR2A
SCHEMBL5089907 0.74 HTR6 (0.44) HTR6TAAR1HTR7HTR2BCYP2D6
SCHEMBL5093168 0.73 HTR6 (0.40) HEXAHEXBHTR6TAAR1HTR1A
SCHEMBL5089797 0.72 HTR6 (0.41) HEXAHEXBHTR6HTR1AHTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1517909-B1 NOVEL TETRACYCLIC ARYLCARBONYL INDOLES HAVING SEROTONIN RECEPTOR AFFINITY USEFUL AS THERAPEUTIC AGENTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SUVEN LIFE SCIENCES LTD (IN) 2006-10-25 — — EP claimed
US-20050250834-A1 Novel tetracyclic arylcarbonyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical composition containing them SUVEN LIFE SCIENCES LIMITED (IN) 2005-11-10 — — US claimed
US-7317035-B2 Tetracyclic arylcarbonyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them SUVEN LIFE SCIENCES LIMITED (IN) 2008-01-08 — — US disclosed
EP-1517909-B1 NOVEL TETRACYCLIC ARYLCARBONYL INDOLES HAVING SEROTONIN RECEPTOR AFFINITY USEFUL AS THERAPEUTIC AGENTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SUVEN LIFE SCIENCES LTD (IN) 2006-10-25 — — EP disclosed
US-20050250834-A1 Novel tetracyclic arylcarbonyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical composition containing them SUVEN LIFE SCIENCES LIMITED (IN) 2005-11-10 — — US disclosed
EP-1517909-A2 NOVEL TETRACYCLIC ARYLCARBONYL INDOLES HAVING SEROTONIN RECEPTOR AFFINITY USEFUL AS THERAPEUTIC AGENTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM Suven Life Sciences Limited (IN) 2005-03-30 — — EP disclosed
WO-2004000205-A2 NOVEL TETRACYCLIC ARYLCARBONYL INDOLES HAVING SEROTONIN RECEPTOR AFFINITY USEFUL AS THERAPEUTIC AGENTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SUVEN LIFE SCIENCES LIMITED (IN) 2003-12-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050250834-A1 Novel tetracyclic arylcarbonyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical composition containing them TPH1, HTR1A, HTR5A HEXA 3133/4885HEXB 3572/4885HTR6 11/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback